title: Antibacterial drugs in Crohn's disease.
abstract: The evidence of a beneficial role of antibacterial drugs in Crohn's disease is largely empirical. Data accumulate to show that these drugs may well be used as an adjunctive therapy to oral anti-inflammatory drugs. Circumstantial evidence has also been provided that antibacterial drugs are effective in relieving symptoms related to bacterial overgrowth and when used for specific indications such as perianal lesions.
authors: Dipartimento di Medicina Sperimentale e Clinica, Università di Reggio Calabria, Catanzaro, Italy.
authors: F
authors: F
authors: Pallone
authors: M
authors: M
authors: Boirivant
authors: S
authors: S
authors: Fais
authors: F
authors: F
authors: Luzza
authors: P
authors: P
authors: Doldo
authors: G
authors: G
authors: Monteleone
authors: A
authors: A
authors: Aloi
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000904:Antibiotics, Antitubercular / Q000627:therapeutic use; D001424:Bacterial Infections / Q000188:drug therapy*; D003424:Crohn Disease / Q000188:drug therapy* / Q000382:microbiology; D003622:Dapsone / Q000627:therapeutic use; D006801:Humans; D007408:Intestinal Absorption / Q000502:physiology; D008795:Metronidazole / Q000493:pharmacokinetics / Q000627:therapeutic use; D012294:Rifamycins / Q000493:pharmacokinetics / Q000627:therapeutic use; D000078262:Rifaximin
chemical_list: D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; D000904:Antibiotics, Antitubercular; D012294:Rifamycins; D008795:Metronidazole; D003622:Dapsone; D000078262:Rifaximin